GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation

Author:

Fox Keith A A1ORCID,Virdone Saverio2ORCID,Pieper Karen S2ORCID,Bassand Jean-Pierre23ORCID,Camm A John4ORCID,Fitzmaurice David A5ORCID,Goldhaber Samuel Z6,Goto Shinya7ORCID,Haas Sylvia8ORCID,Kayani Gloria2,Oto Ali9ORCID,Misselwitz Frank10ORCID,Piccini Jonathan P11ORCID,Dalgaard Frederik12ORCID,Turpie Alexander G G13ORCID,Verheugt Freek W A14ORCID,Kakkar Ajay K215ORCID,

Affiliation:

1. Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK

2. Thrombosis Research Institute, Manresa Road, London, SW3 6LR, UK

3. Department of Cardiology, University of Besançon, Boulevard Fleming, 25000 Besançon, France

4. Cardiology Clinical Academic Group Molecular & Clinical Sciences Research Institute, St George's University of London, Cranmer Terrace, Tooting, London SW17 0RE,UK

5. Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK

6. Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA

7. Department of Medicine (Cardiology), Tokai School of medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1143, Japan

8. Department of Medicine, Formerly Technical University of Munich, Normannenstr. 34a, Munich 80333, Germany

9. Department of Cardiology, Memorial Ankara Hospital, Sihhiye, 06100, Ankara, Turkey

10. Formerly, Bayer AG, Müllerstraße 178, 13353 Berlin, Germany

11. Duke Clinical Research Institute, 40 Duke Medicine Circle, Clinic 2F/2G, Durham, NC 27710, USA

12. Department of Cardiology, Herlev & Gentofte Hospital, 2900 Hellerup, Copenhagen, Denmark

13. Department of Medicine, McMaster University, 237 Barton St E Hamilton, Ontario L8L 2X2, Canada

14. Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Oosterpark 9, NL-1091-AC Amsterdam, Netherlands

15. University College London, Gower St, London WC1E 6BT, UK

Abstract

Abstract Aims To determine whether the Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to assess how this risk tool performs compared with CHA2DS2-VASc and HAS-BLED. Methods and results Potential predictors of events included demographic and clinical characteristics, choice of treatment, and lifestyle factors. A Cox proportional hazards model was identified for each outcome by least absolute shrinkage and selection operator methods. Indices were evaluated in comparison with CHA2DS2-VASc and HAS-BLED risk predictors. Models were validated internally and externally in ORBIT-AF and Danish nationwide registries. Among the 52 080 patients enrolled in GARFIELD-AF, 52 032 had follow-up data. The GARFIELD-AF risk tool outperformed CHA2DS2-VASc for all-cause mortality in all cohorts. The GARFIELD-AF risk score was superior to CHA2DS2-VASc for non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in internal validation and in the Danish AF cohort. In very low- to low-risk patients [CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)], the GARFIELD-AF risk score offered strong discriminatory value for all the endpoints when compared to CHA2DS2-VASc and HAS-BLED. The GARFIELD-AF tool also included the effect of oral anticoagulation (OAC) therapy, thus allowing clinicians to compare the expected outcome of different anticoagulant treatment decisions [i.e. no OAC, non-vitamin K antagonist (VKA) oral anticoagulants, or VKAs]. Conclusions The GARFIELD-AF risk tool outperformed CHA2DS2-VASc at predicting death and non-haemorrhagic stroke, and it outperformed HAS-BLED for major bleeding in overall as well as in very low- to low-risk group patients with AF. Clinical trial registration URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF: NCT01090362, ORBIT-AF I: NCT01165710; ORBIT-AF II: NCT01701817.

Funder

KANTOR CHARITABLE FOUNDATION

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Health Policy

Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3